Pfizer Inc. (NYSE:PFE) Stake Lowered by Winch Advisory Services LLC

Winch Advisory Services LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,212 shares of the biopharmaceutical company’s stock after selling 1,469 shares during the period. Winch Advisory Services LLC’s holdings in Pfizer were worth $469,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Olistico Wealth LLC purchased a new position in shares of Pfizer during the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the second quarter worth $29,000. Quarry LP bought a new stake in Pfizer in the second quarter worth $31,000. Trivant Custom Portfolio Group LLC boosted its holdings in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new stake in Pfizer in the second quarter worth $34,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 1.0 %

Shares of PFE opened at $28.93 on Tuesday. The company has a 50-day simple moving average of $29.07 and a 200-day simple moving average of $28.47. The firm has a market capitalization of $163.93 billion, a P/E ratio of -482.17, a P/E/G ratio of 1.02 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the prior year, the business posted $0.67 earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.81%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. Barclays upped their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Thursday, October 3rd. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.